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Abstract
Introduction: Evaluating the expression of signaling molecule proteins from the mitogen-activated protein kinase 
(MAPK) pathway and the phosphatidylinositol-3-kinase (PI3K) pathway in invasive breast cancers may identify 
prognostic marker(s) associated with early relapse.
Methods: Immunohistochemical analyses of phosphatase and tensin homologue deleted on chromosome 10 (PTEN), 
PI3K-p110α, phospho-AKT, phospho-p70S6 kinase, phospho-S6 ribosomal protein, phospho-RAF, phospho-p44/42 
MAPK, and heat-shock protein 90 (HSP90) were performed on tumor samples from 212 patients with invasive breast 
cancer. Statistically significant relations between protein expression, clinicopathologic factors, and relapse-free survival 
(RFS) were analyzed.
Results: Expression of HSP90 was associated with 5-year RFS, as well as T stage, N stage, histologic grade, estrogen 
receptor (ER) expression, human epidermal growth factor receptor 2 (HER2) expression, and the Ki-67 proliferation 
index. On multivariate analysis, coexpression of HSP90 and PI3K-p110α or expression of HSP90 along with PTEN loss 
demonstrated significantly worse RFS. In subgroup analyses, both exhibited strong prognostic significance in HER2-
positive cases, but not in HER2-negative cases.
Conclusions: The coexpression of HSP90 with PI3K-p110α or expression of HSP90 along with PTEN loss has a potential 
as a molecular prognostic marker to predict early relapse in patients with invasive breast cancers.
Introduction
Disruption of critical cell-signaling pathways responsible
for cell growth and survival has been shown to contribute to
atypical cell proliferation, to metastatic competence of
breast cancer cells, and may be responsible for therapeutic
resistance of some breast cancers. In the field of targeted
breast cancer therapy, several prognostic markers including
clinical stage [1], histologic grade [2], estrogen receptor
(ER)/progesterone receptor (PR) status [3-5], human epi-
dermal growth factor receptor-2 (HER2) [6,7], and the Ki-
67 proliferation index [8] have already been identified and
validated. Additional molecular markers that have potential
prognostic significance also have been identified.
HER2 is a cell-surface receptor tyrosine kinase (RTK),
which is amplified in one fourth of breast cancers and con-
fers a more aggressive clinical course and worse prognosis
[6,7]. The intracellular catalytic domain of HER2 receptor
can be phosphorylated by the formation of homodimeric or
heterodimeric kinase-active complexes, and it ultimately
leads to activation of signal-transduction pathways that pro-
mote proliferation or survival of breast cancer cells: the
mitogen-activated protein kinase (MAPK) and the phos-
phatidylinositol-3-kinase (PI3K) pathways are two major
signal-transduction pathways of the ErbB family RTKs
involved in proliferation and survival [reviewed in [9]].
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AKT, p70 S6 kinase, and ribosomal protein S6 are among
the most important and representative downstream mole-
cules of these signaling pathways [10]. Another important
protein of the PI3K pathway is the phosphatase and tensin
homologue deleted on chromosome 10 (PTEN) [11]. PTEN
antagonizes PI3K function and negatively regulates AKT
activity. Conversely, heat-shock protein 90 (HSP90) is a
chaperone required for the stability and function of these
proteins, especially ER, HER2, AKT, and RAF [12]. Previ-
ous studies evaluated the prognostic significance of these
molecular markers. Several of these proteins have shown
potential as prognostic markers; however, these studies
have examined each molecule individually [13-20].
In the present study, we analyzed the expression of target
molecules involved in the HER2-associated signaling path-
way including PTEN, p110α subunit of PI3K (PI3K-
p110α), phosphorylated AKT (p-AKT), phosphorylated
p70 S6 kinase (p-p70S6K), phosphorylated ribosomal pro-
tein S6 (p-S6), phosphorylated RAF (p-RAF), phosphory-
lated p44/42 MAPK (p-p44/42 MAPK), and HSP90.
Additionally, the prognostic significance of these molecular
markers, individually, as well as in combination with other
established prognostic factors, was investigated.
Expression of HSP90 from invasive breast cancer was
associated with an increased risk of early recurrence. Coex-
pression of HSP90 and PI3K or expression of HSP90 in
combination with the loss of PTEN was associated with sig-
nificantly worse RFS. In subgroup analysis, coexpression
of HSP90 and PI3K-p110α or expression of HSP90 along
with PTEN loss showed strong prognostic significance in
patients with HER2-positive cancers, but not with HER2-
negative cancer.
Thus, these results show that the coexpression of HSP90
with PI3K-p110α or the expression of HSP90 along with
PTEN loss has a potential as a molecular prognostic marker
for early relapse in patients with invasive breast cancers.
Materials and methods
Patients and samples
Tissue samples from 212 patients who underwent surgical
resection for primary invasive breast cancer at Seoul
National University Bundang Hospital from May 2003 to
November 2005 were collected. Informed consent for
pathologic evaluation was obtained from patients from
whom tissue samples were taken. After surgery, most
patients were treated with the standard practice guidelines
and have been followed up regularly.
Paraffin-embedded tumor samples from the 212 patients
with invasive breast cancer were obtained in accordance
with a protocol approved by the institutional review board
of Seoul National University Bundang Hospital. The fol-
lowing histopathologic variables were determined by
reviewing pathology reports and hematoxylin and eosin-
stained sections: tumor size, lymph node metastasis, histo-
logic subtype, and histologic grade. Tissue microarrays
were constructed for a high-throughput study as previously
described [21], as well as for immunohistochemical stain-
ing.
Immunohistochemical analysis
After staining optimization by using positive and negative
controls, eight antibodies that provided satisfactory results,
together with standard prognostic biomarkers, including
ER, PR, HER2, and Ki-67, were used for the study (Addi-
tional file 1). Immunohistochemical staining was carried
out by using the DAKO Envision detection kit (Dako,
Carpinteria, CA). In brief, tissue array blocks were cut into
4 μm-thick sections, dried, deparaffinized, and rehydrated.
Antigen retrieval was performed in a microwave oven for
15 min in 10 mM citrate buffer, pH 6.0, and endogenous
peroxidase activity was blocked with a 3% H2O2-methanol
solution. The slides were blocked with 10% normal goat
serum for 10 minutes and were incubated with an appropri-
ately diluted primary antibody for an hour at room tempera-
ture or overnight at 4°C. The slides were then probed with
HRP-labeled polymer conjugated to secondary antibody for
30 minutes. Diaminobenzidine was used as a chromogen,
and the sections were counterstained with Mayer's hema-
toxylin.
Definition of breast tumor subtypes
Breast tumor subtypes were defined as follows: luminal A
(ER+  and/or PR+, HER2-), luminal B (ER+ and/or PR+,
HER2+), HER2+/ER- (ER-, PR-, HER2+), and triple nega-
tive (ER-, PR-, HER2-). HER2 positivity was determined
based on FISH results from the previous study [21].
Interpretation and statistical analysis
Staining results were interpreted by a breast pathologist
who was blinded to patient outcomes. The expression of
ER, PR, and Ki-67 was scored as positive if >10% nuclear
staining was found. Immunohistochemical scoring of sig-
naling molecules was based on a semiquantitative method
according to the percentage of positive cells and the inten-
sity of staining. Staining in either the cytoplasmic or the
nuclear compartment was all considered positive (Addi-
tional file 1). The percentage of positive cells was scored as
follows: 0, no staining or staining in <5% of the tumor
cells; 1, staining in 5% to 25% of the cells; 2, staining in
26% to 50% of the cells; 3, staining in 51% to 75% of the
cells; and 4, staining in >75% of the cells. The staining
intensity was scored as 0 (negative), 1 (weak), 2 (moder-
ate), or 3 (strong). For all signaling molecules except
PTEN, cases with >5% of positive tumor cells with moder-
ate to strong intensity were grouped as positive. For PTEN,
cases with complete loss of staining were grouped as nega-
tive, and cases with any staining, as positive.Song et al. Breast Cancer Research 2010, 12:R20
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All data were analyzed with SPSS 12.0 for Windows
(SPSS Inc., Chicago, IL). The Spearman correlation test
was used to analyze the association between variables.
Relapse-free survival (RFS) was measured from the date of
diagnosis to the date of locoregional recurrence, distant
metastasis, or death. Kaplan-Meier survival curves for RFS
were constructed, and differences were determined by log-
rank test. To test the independent prognostic significance of
certain markers, each marker was included with the stan-
dard prognostic factors into a Cox proportional hazards
model.
Results
Patients and tumor characteristics are presented in Table 1.
At the time of the analysis, the median follow-up was 5
years (range, 3 to 6 years). There were seven (3%) locore-
gional recurrences as first events and 19 (9%) distant
metastases. Eleven patients had died of recurrent or meta-
static breast cancer.
PTEN loss was found in 26.9%; PI3K-p110α was
expressed in 66.3%; p-AKT, in 28.3%; p-p70S6K, in
75.8%; p-S6, in 62.7%; p-RAF, in 45.7%; p-p44/42 MAPK,
in 26.8%; and HSP90, in 63.5% of the 212 tissue samples
of invasive breast cancers (Table 2; Figure 1).
Table 3 summarizes the correlations between the markers
analyzed and the histopathologic features of the tumors.
Table 1: Patients and tumor characteristics
Characteristics Number of patients (%)
Age (years)
<40 33 (15.6)
≥40 179 (84.4)
Histology
Invasive ductal 205 (96.7)
Invasive lobular 7 (3.3)
Tumor stage
T1--T2 199 (93.9)
T3--T4 13 (6.1)
Nodal stage
N0 106 (50.0)
N1--N3 106 (50.0)
Histologic grade
Grade I--II 116 (54.7)
Grade III 89 (42.0)
ER
Negative 70 (33.0)
Positive 142 (67.0)
PR
Negative 113 (53.3)
Positive 99 (46.7)
HER2
Negative 168 (79.2)
Positive 44 (20.8)
Ki-67 index
<10% 120 (56.6)
≥10% 91 (42.9)
ER = estrogen receptor; HER2 = human epidermal growth factor receptor-2; PR = progesterone receptor.Song et al. Breast Cancer Research 2010, 12:R20
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Expression of p-AKT was associated with high histologic
grade (P = 0.006) and HER2 amplification (P < 0.001).
Expression of p-p70S6K was correlated with high histo-
logic grade (P = 0.035), ER negativity (P < 0.001), and
HER2 amplification (P < 0.001). A significant correlation
was seen between p-S6 and high histologic grade (P  <
0.001), ER negativity (P < 0.001), HER2 amplification (P =
0.004), and high Ki-67 proliferation index (P < 0.001). The
expression of p-AKT, p-p70S6K, and p-S6, which are
involved in the PI3K pathway, demonstrated a significant
positive correlation with each other. Expression of p-RAF
and p-p44/42 MAPK, which are constituents of the MAPK
pathway, also exhibited a positive correlation (P < 0.001).
HSP90 expression showed a significant positive correlation
with p-RAF expression (P = 0.047). Although not statisti-
cally significant, HSP90 expression demonstrated a trend
toward correlation with the presence of p-AKT (P = 0.062),
but not with ER or HER2 (P = 0.178 and P = 0.471, respec-
tively).
In univariate analyses, several conventional prognostic
factors were identified as significant predictive factors for
RFS, including tumor stage, nodal stage, histologic grade,
and amplification of HER2. ER had only marginal signifi-
cance for a correlation with RFS (P = 0.052). Of the other
signaling molecules analyzed, HSP90 was significantly
associated with RFS (P = 0.039; Figure 2A). PI3K-p110α
had a trend toward poor RFS (P  = 0.058; Figure 2B).
PTEN, p-AKT, p-p70S6K, p-S6, p-RAF, and p-p44/42
MAPK were not associated with RFS (Table 4).
HSP90 did not remain significantly correlated to RFS (P
= 0.269) in a multivariate analysis accounting for standard
factors such as T stage (T1-2 versus T3-4), N stage (N0 ver-
sus N1-3), histologic grade (Grade 1-2 versus 3), ER, and
HER2. However, when the expressions of both HSP90 and
Figure 1 Immunohistochemical analyses of various signaling molecules in MAPK and PI3K pathways. Representative examples of immuno-
histochemical staining patterns observed in invasive breast cancers. p-AKT (a) shows predominant nuclear staining with weak cytoplasmic staining in 
this case. PI3K-p110α (b), p-S6 (c), p-RAF (d), and HSP90 (e) show strong cytoplasmic staining. The p-p70S6K (f), p-p44/42 MAPK (g), and PTEN (h) are 
localized in both cytoplasmic and nuclear compartments.
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Table 2: Expression rates of the signaling proteins tested
Marker Number of positive cases/Total number of cases (%)
PTEN loss 57/212 (26.9)
PI3K-p110α 138/208 (66.3)
p-Akt 60/212 (28.3)
p-p70S6K 160/211 (75.8)
p-S6 131/209 (62.7)
p-RAF 96/210 (45.7)
p-MAPK 56/209 (26.8)
HSP90 134/211 (63.5)
HSP90 = heat-shock protein 90; MAPK = mitogen-activated protein kinase; PI3K = phosphatidylinositol-3-kinase; PTEN = phosphatase and 
tensin homologue deleted on chromosome 10.S
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Table 3: Correlation matrix of histopathologic variables and expression of each signaling protein
≥ T3 LN+ Grade 3 ER HER2 Ki-67 PTEN PI3K-p110α p-Akt p-p70S6K p-S6 p-Raf p-p44/42-MAPK
≥ T3 -
LN+ 0.010 -
Grade 3 0.044 0.185 -
ER 0.100 0.772  < 0.001 -
HER2 0.361 0.042  < 0.001  < 0.001 -
Ki-67 0.821 0.236  < 0.001  < 0.001  < 0.001 -
PTEN 0.746 0.644 0.015 0.042 0.753 0.031 -
PI3K-p110α 0.151 0.770 0.236 0.159 0.085 0.768 0.552 -
p-Akt 0.668 0.762 0.006 0.702  < 0.001 0.060 0.284 0.211 -
p-p70S6K 0.925 0.139 0.035  < 0.001  < 0.001 0.057 0.780 0.192 0.002 -
p-S6 0.930 0.606  < 0.001  < 0.001 0.004  < 0.001 0.172 0.553 0.011  < 0.001 -
p-Raf 0.974 0.671 0.509 0.770 0.328 0.800 0.343 0.266  < 0.001  < 0.001 0.364 -
p-p44/42 MAPK 0.756 0.562 0.238 0.623 0.841 0.118 0.428 0.334 0.147 0.015 0.974  < 0.001 -
HSP90 0.302 0.510 0.588 0.178 0.471 0.759 0.481 0.065 0.062 0.153 0.208 0.047 0.278
Variables found to be significant (P < 0.05) are shown in bold. ER = estrogen receptor; HER2 = human epidermal growth factor receptor-2; HSP90 = heat-shock protein 90; MAPK = mitogen-activated protein kinase; 
PI3K = phosphatidylinositol-3-kinase; PTEN = phosphatase and tensin homologue deleted on chromosome 10.Song et al. Breast Cancer Research 2010, 12:R20
http://breast-cancer-research.com/content/12/2/R20
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PI3K-p110α were included in the Cox proportional hazards
model, the coexpression of HSP90 and PI3K-p110α was
identified as an independent prognostic factor for RFS
(Hazard ratio (HR), 2.99; 95% confidence interval (CI),
1.18 to 7.60; P = 0.021), as did T stage and N stage. The
combination of HSP90 expression and PTEN loss was also
a significant predictor for RFS in multivariate analysis (HR,
2.83; 95% CI, 1.11 to 7.20; P = 0.029). RFS curves plotted
in relation to the expression status of HSP90 and either
PI3K-p110α or PTEN are shown in Figure 3A and 3B,
respectively. Other combined expression of HSP90 with p-
AKT or p-p70S6K or p-S6 or p-RAF or p-p44/42 MAPK
failed to show prognostic significance in multivariate anal-
ysis.
When the tumors were classified according to intrinsic
subtypes, 131 (62%) cases were classified as luminal A, 18
(9%) cases as luminal B, 26 (13%) cases as HER2+/ER-,
and 37 (18%) cases as triple-negative subtype. Table 5
shows expression rates of HSP90, PI3K-p110α, and PTEN
loss within each intrinsic subtype. Triple-negative cases
exhibited a significantly higher rate of loss of PTEN com-
pared with those of other subtypes. The prognostic value of
HSP90, PI3K-p110α, and PTEN was also evaluated accord-
ing to the individual intrinsic subtype. Although not statisti-
cally significant, HSP90 expression demonstrated a trend
toward correlation with worse RFS in the triple-negative
subtype (Figure 4A). Coexpression of HSP90 and PI3K-
p110α was a significant prognostic factor for RFS in lumi-
nal B subtype (Figure 4B). HSP90 expression, along with
loss of PTEN, also showed a marginal prognostic signifi-
cance in HER2+/ER- and luminal B subtypes, respectively
(Figure 4C and 4D).
When tumors were clustered by HER2 status, coexpres-
sion of HSP90 and PI3K-p110α predicted significantly
worse RFS in patients with HER2-positive cases that
included luminal B and HER2+/ER- subtypes, whereas it
failed to show prognostic significance in HER2- cases (Fig-
ure 5). The HSP90 expression along with loss of PTEN also
exhibited a strong prognostic significance in patients with
HER2-positive cases, but not with HER2-negative cases
(Figure 6).
Discussion
In recent years, improvements in the understanding of the
altered molecular events leading to breast cancer have led
to the identification of new molecular targets and the devel-
Figure 2 Kaplan-Meier survival curves showing the probability of 
relapse-free survival for patients with invasive breast cancer in 
relation to the expression of HSP90 (a) and PI3K-p110α (b).
Table 4: Predictive factors for relapse-free survival*
Variable P value
T stage  < 0.001
N stage  < 0.001
Histologic grade 0.033
ER 0.052
PR 0.076
HER2 0.016
Ki-67 0.015
PTEN 0.397
PI3K-p110α 0.058
p-Akt 0.681
p-p70S6K 0.342
p-S6 0.504
p-Raf 0.729
p-p44/42 MAPK 0.366
HSP90 0.039
*Based on univariate analysis. Variables found to be significant (P 
< 0.05) are shown in bold.ER = estrogen receptor; HER2 = human 
epidermal growth factor receptor-2; HSP90 = heat-shock protein 
90; MAPK = mitogen-activated protein kinase; PI3K = 
phosphatidylinositol-3-kinase; PR = progesterone receptor; PTEN 
= phosphatase and tensin homologue deleted on chromosome 
10.Song et al. Breast Cancer Research 2010, 12:R20
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opment of new targeted therapies. Identification of the
prognostic significance of HER2 and its targeted therapy
provides the best examples of proof of concept [22]. Other
potential negative prognostic factors represent a new oppor-
tunity for therapeutic targeting to improve treatment out-
comes [23]. Growing evidence supports the dependence of
cancer cells on aberrant PI3K signaling for survival. PI3K
generates specific inositol lipids (PIP2 and PIP3) that have
been implicated in the regulation of cell proliferation, dif-
ferentiation, survival, and angiogenesis [reviewed in
[24,25]]. Recently, several groups reported that 18% to 40%
of human breast cancers harbor somatic mutations of the
p110α catalytic subunit of PI3K [26], resulting in constitu-
tive activation of PI3K signaling. The PTEN gene dephos-
phorylates PIP3, the critical lipid second messenger of
PI3K. The loss of PTEN leads to accumulation of PIP3 and
increases PI3K-AKT signaling [27]. Berns and colleagues
Figure 3 Kaplan-Meier survival curves showing the probability of 
relapse-free survival for patients with invasive breast cancer in 
relation to the expression status of HSP90 and either PI3K-p110α 
(a) or PTEN loss (b).
Figure 4 Kaplan-Meier survival curves showing the probability of 
relapse-free survival for patients with invasive breast cancer in 
relation to the expression of HSP90 in triple-negative subtype (a), 
coexpression of HSP90 and PI3K-p110α in luminal B subtype (b), 
expression of HSP90 along with PTEN loss in HER2+/ER-subtype 
(c) and in luminal B subtype (d).
Table 5: Expression of HSP90, PI3K-p110α, and PTEN loss according to intrinsic subtypes
Luminal A
(n = 131)
Luminal B
(n = 18)
Triple negative
(n = 37)
HER2+/ER-
(n = 26)
P value
n (%) n (%) n (%) n (%)
HSP90 86 (66) 13 (72) 18 (49) 17 (65) 0.208
PI3K-p110α 79 (62) 13 (72) 25 (68) 21 (81) 0.296
PTEN loss 29 (22) 6 (33) 17 (46) 5 (19) 0.023
HSP90 = heat-shock protein 90; PI3K = phosphatidylinositol-3-kinase; PTEN = phosphatase and tensin homologue deleted on chromosome 
10.Song et al. Breast Cancer Research 2010, 12:R20
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[28] reported that activation of the PI3K pathway through
loss of the tumor suppressor PTEN or through oncogenic
stimulation of PI3K can mediate trastuzumab resistance.
The current study also suggests that a potential prognostic
significance of PI3K signaling may predict early relapse in
patients with invasive breast cancers.
We previously reported that inhibitors targeting the PI3K-
AKT pathway enhanced radiation-induced cell killing in
human cancer cells [29]. We also have shown that targeting
the PI3K-AKT-mTOR pathway can be an alternative strat-
egy to overcome therapeutically resistant breast cancer cells
with an activated HER2 signaling pathway. Impairment of
DNA-damage repair increased apoptosis and autophagy
and was identified as a mechanistic elements of increased
breast cancer cell death [30].
The majority of breast cancers involve multiple molecu-
lar abnormalities that are likely to be involved in malignant
progression. It is possible that several different molecules
from diverse pathways have synergistic properties that pro-
mote malignant relapse or metastasis. In that situation,
HSP90 could be a pivotal key molecule, as its chaperone
function ensures the correct conformation, activity, intracel-
lular localization, and proteolytic turnover of a range of
proteins involved in cell growth, differentiation, and sur-
vival [12]. This molecular chaperon is essential for the sta-
bility and function of many oncogenic client proteins,
which contributes to the hallmark trait of cancers such as
ER, HER2, and AKT [31]. The inhibition of multiple tar-
gets through the abrogation of HSP90 could be more effec-
tive in the management of breast cancers, because its
inhibition counteracts multiple oncogenic molecules and
prosurvival signaling pathways at the same time.
Additional data support the identification of HSP90 as an
important molecular target relevant to breast cancers.
HER2, which is associated with poor prognosis in breast
cancer, is one of the most important client proteins of
HSP90, and HSP90 inhibitors have shown antitumor activ-
ity in an HER2-driven xenograft model [32]. Additionally,
HSP90 inhibitors have been known to bind selectively to
HSP90 in cancerous cells versus normal cells [33]. Breast
cancer cells resistant to conventional chemotherapy, radia-
tion therapy, and trastuzumab are known to involve the
PI3K signaling pathway. The key molecule of this pathway,
AKT, is also an important client protein of HSP90. A recent
report suggests that the expression of HSP90 may be asso-
ciated with poor clinical outcomes in patients with breast
Figure 5 Kaplan-Meier survival curves showing the probability of 
relapse-free survival for patients with invasive breast cancer in 
relation to the coexpression of HSP90 and PI3K-p110α in patients 
who are HER2 positive (a) or negative (b).
Figure 6 Kaplan-Meier survival curves showing the probability of 
relapse-free survival for patients with invasive breast cancer in 
relation to HSP90 expression along with PTEN loss in patients 
who are HER2 positive (a) or negative (b).Song et al. Breast Cancer Research 2010, 12:R20
http://breast-cancer-research.com/content/12/2/R20
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cancers [20]. The current study provides direct evidence
that the expression of HSP90 predicts early relapse in
patients with invasive breast cancers and validates the sig-
nificance of HSP90 as a clinically significant therapeutic
target.
Breast cancer is a heterogeneous entity, and the prognos-
tic importance of intrinsic subtype has been extensively
studied by gene-expression profiling. Almost all tumors
having an intrinsic subtype of basal-like, HER2+ and ER-,
or luminal B were also classified as having a poor 70-gene
profile and high recurrence score [34]. The largest meta-
analysis of gene-expression profiles of 2,833 breast tumors
also revealed connections between traditional prognostic
factors, expression-based subtyping, and prognostic signa-
tures [35]. In accord with the recent report by Marty and
associates [36], triple-negative cases showed significantly
higher rates of loss of PTEN. The exploratory analyses
regarding intrinsic subtype were focused on the prognostic
value of HSP90, PI3K-p110α, and PTEN in each intrinsic
subtype; HSP90 expression exhibited a trend toward worse
prognosis in patients having a triple-negative subtype.
Coexpression of HSP90 and PI3K-p110α was a significant
prognostic factor in patients having luminal B subtype.
When combining the cases having luminal B (HER2+/ER+)
and HER2+/ER-  subtypes, coexpression of HSP90 and
PI3K-p110α or expression of HSP90 along with PTEN loss
demonstrated strong prognostic significance in terms of
RFS in patients with HER2-positive cancers, but not with
HER2-negative cancer.
Conclusions
Taken together, our data demonstrate the potential prognos-
tic value of the coexpression of HSP90 and PI3K or the
expression of HSP90 along with loss of PTEN. This also
serves to refine further the characteristics of breast cancer
patient subgroups with poor prognoses that could develop
into early relapse. Therapeutic strategies that target these
molecules may also be reasonable approaches to improving
therapeutic outcomes for patients with invasive breast can-
cers.
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